What were the rates of clinically significant bleeding among the three treatment groups in the PIONEER AF study?
The rates of clinically significant bleeding were lower in the two groups receiving rivaroxaban than in the VKA group (16.8% in group 1, 18.0% in group 2, and 26.7% in group 3; HR for group 1 group 2 vs group 3, 0.63; 95% CI, 0.50-0.80; P < .001).